These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21477796)

  • 21. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
    Xu YF; Zhang YQ; Xu XM; Song GX
    Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S; Frazer IH; Fernando GJ; Zhou J
    Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Papillomavirus-like particle vaccines for cervical cancer.
    Schiller JT
    Mol Med Today; 1999 May; 5(5):209-15. PubMed ID: 10322313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic DNA immunization against multiple papillomavirus types.
    Gasparić M; Rubio I; Thönes N; Gissmann L; Müller M
    Vaccine; 2007 Jun; 25(23):4540-53. PubMed ID: 17485151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
    Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
    J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prophylactic and therapeutic vaccination against human papillomavirus].
    Brun JL; Riethmuller D
    J Gynecol Obstet Biol Reprod (Paris); 2007 Nov; 36(7):631-41. PubMed ID: 17822860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.
    Baek JO; Seo JW; Kim IH; Kim CH
    Protein Expr Purif; 2011 Feb; 75(2):211-7. PubMed ID: 20716445
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus vaccines--immune responses.
    Stanley M; Pinto LA; Trimble C
    Vaccine; 2012 Nov; 30 Suppl 5():F83-7. PubMed ID: 23199968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes.
    Govan VA
    Ann N Y Acad Sci; 2005 Nov; 1056():328-43. PubMed ID: 16387699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
    Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
    Harper DM
    Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventive and therapeutic HPV vaccines.
    Monie A; Hung CF; Wu TC
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1038-50. PubMed ID: 18058574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
    Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
    Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virus-like particles for the prevention of human papillomavirus-associated malignancies.
    Wang JW; Roden RB
    Expert Rev Vaccines; 2013 Feb; 12(2):129-41. PubMed ID: 23414405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.